MX2020001235A - Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. - Google Patents

Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.

Info

Publication number
MX2020001235A
MX2020001235A MX2020001235A MX2020001235A MX2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A
Authority
MX
Mexico
Prior art keywords
pyrazolo
pyrimidin
dihydro
analogs
compounds
Prior art date
Application number
MX2020001235A
Other languages
English (en)
Inventor
Hui Liu
Brant Clayton Boren
Peter Qinhua Huang
Kevin Duane Bunker
Sunil Paliwal
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2020001235A publication Critical patent/MX2020001235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción se proporcionan compuestos de la Fórmula (I). Tales compuestos, así como sales farmacéuticamente aceptables y composiciones de estos, son útiles para tratar enfermedades o afecciones, que incluyen afecciones caracterizadas por proliferación celular excesiva, tales como el cáncer de mama.
MX2020001235A 2017-08-01 2018-07-31 Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. MX2020001235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539734P 2017-08-01 2017-08-01
PCT/US2018/044580 WO2019028008A1 (en) 2017-08-01 2018-07-31 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Publications (1)

Publication Number Publication Date
MX2020001235A true MX2020001235A (es) 2020-07-20

Family

ID=65233095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001235A MX2020001235A (es) 2017-08-01 2018-07-31 Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.

Country Status (15)

Country Link
US (2) US11124518B2 (es)
EP (1) EP3661918B1 (es)
JP (1) JP7203816B2 (es)
KR (1) KR20200034781A (es)
CN (1) CN111094253B (es)
AR (1) AR112774A1 (es)
AU (1) AU2018312448B2 (es)
BR (1) BR112020002104A2 (es)
CA (1) CA3071405A1 (es)
IL (1) IL272262A (es)
MX (1) MX2020001235A (es)
RU (1) RU2020105058A (es)
SG (1) SG11202000789WA (es)
TW (1) TW201910335A (es)
WO (1) WO2019028008A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019169065A2 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
JP7300460B2 (ja) * 2018-03-09 2023-06-29 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
WO2020210375A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220220115A1 (en) * 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210381A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
MX2021015572A (es) 2019-06-28 2022-04-06 Shanghai Pharmaceuticals Holding Co Ltd Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021127044A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
CA3180664A1 (en) * 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
MX2023012491A (es) * 2021-04-30 2023-11-03 Wigen Biomedicine Tech Shanghai Co Ltd Compuesto ciclico condensado como inhibidor de wee-1, metodo para su preparacion y uso de este.
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023045942A1 (zh) * 2021-09-22 2023-03-30 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2411975T3 (es) * 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
WO2009054332A1 (ja) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
DK3181567T3 (da) * 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20200157112A1 (en) 2020-05-21
AU2018312448B2 (en) 2022-09-15
SG11202000789WA (en) 2020-02-27
RU2020105058A (ru) 2021-09-02
US20210317124A1 (en) 2021-10-14
AR112774A1 (es) 2019-12-11
IL272262A (en) 2020-03-31
US11124518B2 (en) 2021-09-21
AU2018312448A1 (en) 2020-02-13
WO2019028008A1 (en) 2019-02-07
CN111094253A (zh) 2020-05-01
EP3661918B1 (en) 2024-05-08
RU2020105058A3 (es) 2021-11-17
JP7203816B2 (ja) 2023-01-13
CA3071405A1 (en) 2019-02-07
EP3661918A4 (en) 2021-05-12
EP3661918A1 (en) 2020-06-10
BR112020002104A2 (pt) 2020-08-04
TW201910335A (zh) 2019-03-16
CN111094253B (zh) 2023-08-29
JP2020529993A (ja) 2020-10-15
KR20200034781A (ko) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2023009185A (es) Compuestos de benzamida.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
MX2022005780A (es) Moduladores de receptores estrogenicos.
MX2023001876A (es) Derivados de rapamicina.
PH12020551305A1 (en) Pharmaceutical Compounds
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2023011282A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2018004347A (es) Compuestos utiles como inmunomoduladores.
PH12019500480A1 (en) Pyridine compound
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
MX2022007474A (es) Compuestos macrociclicos.
MX2021014458A (es) Compuestos triciclicos.
MX2022002443A (es) Compuestos inhibidores de perk.